

The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having participants complete questionnaires. The study will investigate the effects of diet on quality of life, treatment response, and other disease, microbiome, and immune markers.





Create an alert
Since this trial requires contact information verification, you will receive an email with the information you provided asking for your validation. Only after this verification step your referral will be sent to the study site selected.
To verify your phone, please use one of the verification methods below:
The prescreener preview is complete. You may now close the preview.
